Subscribe
shutterstock_1933953794_postmodern_studio
Postmodern Studio / Shutterstock.com
11 April 2022Big PharmaAlex Baldwin

PTAB grants review of Seagen patent on eve of court’s infringement ruling

The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu (trastuzumab deruxtecan) breast cancer treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Japanese pharma company wins arbitration over cancer drug
16 August 2022   Dispute over the Enhertu began in 2019 | Antibody drug conjugate tech at issue | American Arbitration Association issued final decision.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Japanese pharma company wins arbitration over cancer drug
16 August 2022   Dispute over the Enhertu began in 2019 | Antibody drug conjugate tech at issue | American Arbitration Association issued final decision.

More on this story

Americas
Seagen targets Daiichi in cancer drug suit
22 October 2020   US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
Americas
Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18 November 2020   Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.
Americas
Japanese pharma company wins arbitration over cancer drug
16 August 2022   Dispute over the Enhertu began in 2019 | Antibody drug conjugate tech at issue | American Arbitration Association issued final decision.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York